{"id":"NCT00235755","sponsor":"GlaxoSmithKline","briefTitle":"Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy","officialTitle":"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2008-04","completion":"2008-04","firstPosted":"2005-10-10","resultsPosted":"2011-11-07","lastUpdate":"2017-04-21"},"enrollment":539,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Seizures"],"interventions":[{"type":"DRUG","name":"Retigabine","otherNames":["GKE-841","D-23129"]},{"type":"DRUG","name":"Retigabine","otherNames":["GKE-841","D-23129"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Retigabine 600 mg","type":"EXPERIMENTAL"},{"label":"Retigabine 900 mg","type":"EXPERIMENTAL"}],"summary":"This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 900 mg/day and 600 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to three established antiepileptic drugs (AEDs).","primaryOutcome":{"measure":"Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)","timeFrame":"Baseline (Week -7 through Week 0), DB Phase (Week 1 through Week 16)","effectByArm":[{"arm":"Placebo - Double Blind (DB) Phase (Titration Plus Maintenance)","deltaMin":-15.9,"sd":null},{"arm":"Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance)","deltaMin":-39.9,"sd":null},{"arm":"Retigabine 200 mg TID - DB Phase (Titration Plus Maintenance)","deltaMin":-27.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"0.007"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":70,"countries":["United States","Australia","Belgium","France","Germany","Hungary","Israel","Poland","Russia","South Africa","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["20944074","23342983","22428574","22512894"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":179},"commonTop":["Dizziness","Somnolence","Headache","Fatigue","Nausea"]}}